A pilot study to evaluate the effect of Taeumjowi-tang on obesity in Korean adults: study protocol for a randomised, double-blind, placebo-controlled, multicentre trial

Author:

Park Sunju,Park Jeong-Su,Cheon ChunHoo,Yang Yong Joon,An Changsuk,Jang Bo-Hyoung,Song Yun-Kyung,Go Hoyeon,Lee Ju Ah,Shin Yongcheol,Ko Seong-Gyu

Abstract

Abstract Background Obesity, which is described as excessive or abnormal body fat, increases the risk of diet-related diseases. In Korea and around the world, the prevalence of obesity has grown annually from 1998 to 2008. This growth has continued despite various therapeutic efforts. The discovery of new and alternative treatments for obesity should be considered an important priority. Taeumjowi-tang (TJ001), a traditional Korean medicinal extract consisting of eight herbs, is a widely used herbal remedy for obesity in Korea. However, the efficacy and safety of TJ001 have not been fully investigated in a clinical trial. The purpose of this pilot study is to estimate obesity-related parameters and to assess the efficacy and safety of TJ001. Methods Our study is a randomised, double-blind, placebo-controlled, multicentre clinical trial of Taeumjowi-tang (TJ001). For this study, we will recruit obese Korean patients of both sexes, ages 18 to 65 years, from four university hospitals. A total of 104 subjects will be recruited. The participants will receive either 7 g of TJ001 or a placebo three times daily for 12 weeks. The primary end point will be the rate of subjects who lose at least 5% of their baseline body weight. The secondary end points will be changes in body weight, body mass index, waist circumference, hip circumference, waist/hip circumference ratio, lipid profiles, body fat composition, blood pressure, fasting glucose concentration, C-reactive protein and questionnaires related to the quality of life. The outcomes will be measured every 4 weeks. The study period will be 12 weeks and will include a total of five visits with each subject (at screening and at 0, 4, 8 and 12 weeks). Conclusions The results of our study will inform various estimates of TJ001 and will serve as the basis for a larger-scale trial. This study will assess the efficacy and safety of TJ001 as an alternative herbal remedy for obesity. Trial registration Current Controlled Trials ISRCTN87153759

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Medicine (miscellaneous)

Reference44 articles.

1. World Health Organisation: International Association for the Study of Obesity, International Obesity Task Force: The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. 2000, Sydney: Health Communications

2. Hofbauer KG, Nicholson JR, Boss O: The obesity epidemic: current and future pharmacological treatments. Annu Rev Pharmacol Toxicol. 2007, 47: 565-592. 10.1146/annurev.pharmtox.47.120505.105256.

3. Jee S, Sull J, Park J, Lee S, Ohrr H, Guallar E, Samet J: Body-mass index and mortality in Korean men and women. N Engl J Med. 2006, 355: 779-787. 10.1056/NEJMoa054017.

4. Korea Centers for Disease Control and Prevention (KCDC): National Health and Nutrition Survey Microdata 2008: Prevalence of Obesity. 2009, Chungcheongbuk-do: Korea Centers for Disease Control and Prevention

5. World Health Organization: Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation (WHO Technical Report Series 894). 2000, Geneva: World Health Organization

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3